SGEN Seattle Genetics Inc.

60.48
-0.52  -1%
Previous Close 61
Open 60.41
Price To Book 7.1
Market Cap 9685623306
Shares 160,145,888
Volume 558,938
Short Ratio
Av. Daily Volume 1,215,694

SEC filingsSee all SEC filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181218877
  2. 8-K - Current report 181190480
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181141847
  4. 8-K - Current report 181138972
  5. 8-K - Current report 181095846

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated.
SGN-LIV1A (I-SPY 2)
Neoadjuvant for newly diagnosed Stage 2 or 3 HER2 negative breast cancer
Phase 1/2 trial initiated early 2018.
SGN-LIV1A + KEYTRUDA
First-line triple negative breast cancer (TNBC)
Phase 2 trial initiation announced June 13, 2018.
Tisotumab Vedotin (innovaTV 204 )
Cervical Cancer
Phase 2 pivotal data due 1Q 2019.
Enfortumab vedotin - EV201
Urothelial cancer
Phase 3 trial initiated 2Q 2017.
ADCETRIS and Opdivo
Relapsed Hodgkin Lymphoma
Phase 3 trial initiated mid-2017. Data from Phase 1/2 at ASH 2017 showed a 83% ORR and 62% CR.
ADCETRIS and Opdivo CM-812
Relapsed Hodgkin Lymphoma
Approval announced August 19, 2011.
ADCETRIS
Hodgkin lymphoma and Anaplastic large cell lymphoma
Phase 1/2 clinical hold placed on December 27, 2016 was lifted March 6, 2017. Enrollment halted June 19, 2017 due to safety.
Vadastuximab Talirine (SGN-CD33A)
Myelodysplastic syndrome (MDS)
Phase 1b updated data at SABCS December 7, 2017.
(Tucatinib ONT-380) and T-DM1
HER2+ Metastatic Breast Cancer (MBC)
Phase 2 enrollment to be completed mid-2019.
(Tucatinib ONT-380) + Herceptin and Xeloda - HER2CLIMB trial
HER2+ Metastatic Breast Cancer (MBC)
Phase 3 trial discontinued due to higher rate of deaths - June 19, 2017.
Vadastuximab Talirine (CASCADE)
Acute myeloid leukemia (AML) - cancer
sBLA approval announced March 20, 2018. PDUFA date under priority review was May 1, 2018.
ADCETRIS in combination with chemotherapy ECHELON-1
Frontline Hodgkin lymphoma
Phase 2 trial initiated 3Q 2016.
SGN-CD19A
Frontline DLBCL cancer
FDA Approval announced November 16, 2018.
ADCETRIS in combination with chemotherapy - ECHELON-2
Frontline CD30-positive mature T-cell lymphomas - cancer
Approved August 17, 2015 under priority review.
ADCETRIS - AETHERA
Post-transplant Hodgkin lymphoma (HL) cancer
Approval announced November 9, 2017.
ADCETRIS
Cancer - ALCANZA trial for relapsed CD30-positive cutaneous T-cell lymphoma
Phase 1b trial has been initiated - noted February 6, 2018.
Enfortumab vedotin and pembrolizumab
2nd-line Urothelial cancer
Phase 1b/2 trial has been initiated.
Ladiratuzumab Vedotin
Triple negative breast cancer (TNBC)
Presentation at ASCO June 2018. ORR 41%.
Enfortumab vedotin
Urothelial cancer
Phase 3 trial initiation announced July 9, 2018.
Enfortumab vedotin - EV-301
Urothelial cancer
Phase 2 dosing has commenced - noted July 12, 2018.
Tisotumab Vedotin (innovaTV 207)
Solid tumors
Phase 1/2 updated data presented at ESMO October 20. 2018.
Tisotumab Vedotin (innovaTV 201)
Recurrent Cervical Cancer

Latest News

  1. Understanding Seattle Genetics’ Operational Performance
  2. What Seattle Genetics’ Bottom-Line Trend Indicates
  3. How’s Seattle Genetics Positioned?
  4. Report: Developing Opportunities within Covanta Holding, Zscaler, Avaya, Seattle Genetics, Viad, and Canada Goose — Future Expectations, Projections Moving into 2019
  5. See what the IHS Markit Score report has to say about Seattle Genetics Inc.
  6. Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas
  7. Seattle Genetics Highlights Additional Analyses from ECHELON-1 Phase 3 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma at ASH Annual Meeting
  8. Seattle Genetics Highlights Multiple Data Sets Evaluating the Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) at ASH Annual Meeting
  9. Seattle Genetics opening Bay Area office to attract talent it can't lure to Bothell
  10. Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting
  11. What You Must Know About Seattle Genetics Inc’s (NASDAQ:SGEN) Financial Health
  12. Seattle Genetics (SGEN) Looks Good: Stock Adds 5.6% in Session
  13. Today's Research Reports on Trending Tickers: Amarin and Seattle Genetics
  14. Seattle Genetics stock jumps 6% after new FDA approval for lymphoma treatment
  15. Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30-Expressing Peripheral T-Cell Lymphomas
  16. Seattle Genetics' Adcetris Gets Breakthrough Therapy Status
  17. FDA Grants Breakthrough Therapy Designation to ADCETRIS® (Brentuximab Vedotin) for Frontline Peripheral T-Cell Lymphomas

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181218877
  2. 8-K - Current report 181190480
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181141847
  4. 8-K - Current report 181138972
  5. 8-K - Current report 181095846
  6. CT ORDER - Confidential treatment order 18996542
  7. 8-K - Current report 18972603
  8. 424B7 - Prospectus [Rule 424(b)(7)] 18972573
  9. S-8 - Securities to be offered to employees in employee benefit plans 18972543
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 18972494